These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 25831719)

  • 21. A nurse's understanding of trials in oncology.
    Monahan ML; Seymour SF
    Fla Nurse; 1986; 34(10):19. PubMed ID: 3641758
    [No Abstract]   [Full Text] [Related]  

  • 22. From traditional molecular biology to network oncology.
    Ziogas DE; Katsios C; Roukos DH
    Future Oncol; 2011 Feb; 7(2):155-9. PubMed ID: 21345133
    [No Abstract]   [Full Text] [Related]  

  • 23. Cancer clinical trials: development and implementation.
    Vail DM
    Vet Clin North Am Small Anim Pract; 2007 Nov; 37(6):1033-57; v. PubMed ID: 17950881
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Evaluation of tumor size response metrics to predict survival in oncology clinical trials.
    Bruno R; Mercier F; Claret L
    Clin Pharmacol Ther; 2014 Apr; 95(4):386-93. PubMed ID: 24419563
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Issues and progress with protein kinase inhibitors for cancer treatment.
    Dancey J; Sausville EA
    Nat Rev Drug Discov; 2003 Apr; 2(4):296-313. PubMed ID: 12669029
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Oncology drug development: what is changing?
    Yancey MA
    Clin J Oncol Nurs; 2008 Oct; 12(5):713-5. PubMed ID: 18842527
    [No Abstract]   [Full Text] [Related]  

  • 27. Compressing drug development timelines in oncology using phase '0' trials.
    Kummar S; Kinders R; Rubinstein L; Parchment RE; Murgo AJ; Collins J; Pickeral O; Low J; Steinberg SM; Gutierrez M; Yang S; Helman L; Wiltrout R; Tomaszewski JE; Doroshow JH
    Nat Rev Cancer; 2007 Feb; 7(2):131-9. PubMed ID: 17251919
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [New drugs in early clinical trials and drug resistance--US-Japan joint seminar].
    Ogawa M
    Gan To Kagaku Ryoho; 1990 Apr; 17(4 Pt 1):697-700. PubMed ID: 2321989
    [No Abstract]   [Full Text] [Related]  

  • 29. [Clinical studies in oncology--a challenge for clinical and academic pathology].
    Röcken C
    Dtsch Med Wochenschr; 2013 May; 138(20):1073-6. PubMed ID: 23670265
    [No Abstract]   [Full Text] [Related]  

  • 30. Learning from exceptional drug responders.
    Mullard A
    Nat Rev Drug Discov; 2014 Jun; 13(6):401-2. PubMed ID: 24875081
    [No Abstract]   [Full Text] [Related]  

  • 31. From darkness to light with biomarkers in early clinical trials of cancer drugs.
    Carden CP; Banerji U; Kaye SB; Workman P; de Bono JS
    Clin Pharmacol Ther; 2009 Feb; 85(2):131-3. PubMed ID: 19151637
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Antibody-drug conjugates for cancer: poised to deliver?
    Hughes B
    Nat Rev Drug Discov; 2010 Sep; 9(9):665-7. PubMed ID: 20811367
    [No Abstract]   [Full Text] [Related]  

  • 33. Introduction and commentary: paving the way for biosimilars in oncology, part 2: focus on safety and clinical trial considerations.
    Abraham J
    Semin Oncol; 2014 Feb; 41 Suppl 1():S1-2. PubMed ID: 24560023
    [No Abstract]   [Full Text] [Related]  

  • 34. [Hospital network in pediatric oncology].
    Doz F
    Arch Pediatr; 2006 Jun; 13(6):635-7. PubMed ID: 16697587
    [No Abstract]   [Full Text] [Related]  

  • 35. Clinical trials referral resource. Clinical trials of single-agent oxaliplatin.
    Ivy SP; Blatner G; Cheson BD
    Oncology (Williston Park); 1999 Jul; 13(7):966, 969-70. PubMed ID: 10442343
    [No Abstract]   [Full Text] [Related]  

  • 36. [New therapeutic strategies in oncology].
    Bohuon C
    Ann Pharm Fr; 2010 Jul; 68(4):203-4. PubMed ID: 20637352
    [No Abstract]   [Full Text] [Related]  

  • 37. Rationale for biomarkers and surrogate end points in mechanism-driven oncology drug development.
    Park JW; Kerbel RS; Kelloff GJ; Barrett JC; Chabner BA; Parkinson DR; Peck J; Ruddon RW; Sigman CC; Slamon DJ
    Clin Cancer Res; 2004 Jun; 10(11):3885-96. PubMed ID: 15173098
    [No Abstract]   [Full Text] [Related]  

  • 38. [Design of new protocols. Role of molecular biology units?].
    Milano G
    Bull Cancer; 2008 Oct; 95(10):1003-5. PubMed ID: 19004733
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Oncology drug discovery: planning a turnaround.
    Toniatti C; Jones P; Graham H; Pagliara B; Draetta G
    Cancer Discov; 2014 Apr; 4(4):397-404. PubMed ID: 24706659
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Current status and problems in development of molecular target agents for gastrointestinal malignancy in Japan.
    Boku N
    Jpn J Clin Oncol; 2010 Mar; 40(3):183-7. PubMed ID: 20047861
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.